Literature DB >> 31681207

Sensitivity of Commercially Available Influenza Rapid Diagnostic Tests in the 2018-2019 Influenza Season.

Yuko Sakai-Tagawa1, Seiya Yamayoshi1, Yoshihiro Kawaoka1,2,3.   

Abstract

Epidemics of seasonal influenza caused by H1N1pdm09, H3N2, and type B viruses occur throughout the world. Sporadic human H5 and H7N9 virus infections are also reported in particular regions. To treat influenza patients effectively with antivirals, sensitive and broad-reactive influenza rapid diagnostic tests (IRDTs) are required. Here, we tested the sensitivity of 23 IRDTs during the 2018-2019 influenza season for their ability to detect H1N1pdm09, H3N2, H5N1, H5N6, H7N9, and Victoria- and Yamagata-lineage type B viruses. All IRDTs detected all influenza A and B viruses tested but with different sensitivities. Several IRDTs detected the H5 and H7 viruses and the seasonal viruses with similar sensitivity. Such IRDTs might be useful for diagnosing patients infected with H5 and H7 viruses.
Copyright © 2019 Sakai-Tagawa, Yamayoshi and Kawaoka.

Entities:  

Keywords:  influenza; point-of-care testing; rapid diagnosis test; sensitivity; specificity

Year:  2019        PMID: 31681207      PMCID: PMC6797548          DOI: 10.3389/fmicb.2019.02342

Source DB:  PubMed          Journal:  Front Microbiol        ISSN: 1664-302X            Impact factor:   5.640


Introduction

Influenza virus infection is one of the most prevalent infectious diseases. Seasonal influenza viruses, including H1N1pdm09, H3N2, and type B viruses, cause annual epidemics, despite the use of vaccines against influenza virus. Other subtypes of influenza A virus from other animal species such as chickens and pigs have caused sporadic human cases. For example, highly pathogenic influenza virus subtype H5N1 is circulating among poultry in Asian countries and Egypt and has transmitted to humans (Harfoot and Webby, 2017). Reassortant H5Nx viruses such as H5N2, H5N6, and H5N8 viruses that possess the hemagglutinin (HA) segment of a highly pathogenic H5N1 virus and the neuraminidase (NA) segment of another subtype have emerged and spread in European and North American countries (Nunez and Ross, 2019). H5N6 viruses sporadically infect humans (Yang et al., 2015), and H5N2 viruses replicate well in mammalian hosts (Pulit-Penaloza et al., 2015; Kaplan et al., 2016). Since 2013, human infections with the avian influenza H7N9 virus have been reported (Gao et al., 2013). During the 2016–2017 season, highly pathogenic H7N9 viruses possessing HA with multi-basic amino acids at the cleavage site were isolated from avian and human cases (Zhang et al., 2017; Zhu et al., 2017). It is difficult to prepare vaccines against these H5 and H7 viruses in a timely manner; therefore, the first line of defense against such viruses is antiviral drugs, such as NA inhibitors and an endonuclease inhibitor. For antiviral drugs against influenza to be effective, it is important to identify patients infected with influenza virus as soon as possible. In particular, NA inhibitors (oseltamivir, zanamivir, peramivir, and laninamivir) should be administered within 2 days of symptom onset for optimal efficacy (McNicholl and McNicholl, 2001; Yamashita, 2010). Healthcare providers need a rapid, easy, and sensitive diagnosis test for such purposes. Although basic virologic approaches such as virus isolation and RT-qPCR have been used, they are not suitable in the clinical setting because of time constraints and the need for specialized equipment and technique. Influenza rapid diagnostic tests (IRDTs) are now widely used even at the local, small clinic level in Japan. However, conventional IRDTs that are read by the human eye fail to detect influenza viruses at early timepoints after onset (Watanabe et al., 2009, 2011). To improve this situation, some manufacturers have developed IRDTs that are assessed by analyzers. Here, we examined the sensitivity of 23 IRDTs (5 IRDTs that use analyzers and 18 that are assessed by the human eye) that are available in 2018–2019 to detect various isolates of seasonal influenza A and B viruses as well as human and avian H5Nx and H7N9 viruses, which possess the potential to transmit to humans (Richard and Fouchier, 2016).

Materials and Methods

Diagnostic Tests

The 23 IRDTs listed in Table 1 were evaluated for reactivity and sensitivity according to the manufacturers’ procedures. The lysis buffers that were included in the IRDTs were used for the evaluations. The average minimum virus titer required for a positive reaction in two examinations is shown in the tables.
TABLE 1

Influenza rapid diagnosis tests (IRDTs) evaluated in this study.

IRDTManufacturerCountry of origin of IRDTFormataInput ratiob (%)Minutes to assessc
Statmark FLU Stick-NNichirei BiosciencesJapanTest strip1001–5
RapidTesta colorFLU stickSekisui MedicalUnited StatesTest strip1002–10
QuickVue Rapid SP influDS Pharma BiomedicalUnited StatesTest strip10010
Clearview Exact Influenza A&BAlere MedicalUnited StatesTest strip1008
Espline Influenza A&B-NFujirebioJapanWell6.715
ImmunoAce FluTauns LaboratoriesJapanWell12.53–5
Brightpoc FluNichirei BiosciencesJapanWell13.81–10
Immunofine FLUNichirei BiosciencesJapanWell13.81–5
QuickNavi FluDenka SeikenJapanWell108
QuickNavi-Flu + RSVDenka SeikenJapanWell108
Prorast Flu OneAdtecJapanWell16.78
Finevision InfluenzaAlere MedicalUnited StatesWell105
Nanotrap Flu A⋅BRohto PharmaceuticalJapanWell8.33–8
Quick Chaser Flu A, B (Type H)Mizuho MedyJapanWell255–10
Alsonic FluAlfresa pharmaJapanWell105
Primecheck Flu (Type S)Alfresa pharmaJapanWell20.83–10
RapidTesta FLU⋅NEXTSekisui MedicalUnited StatesWell2415
Spotchem i-Line FluAB-SArkray-factoryJapanWell8.751–10
QuickNavi Flu2Denka SeikenJapanWell + Analyzer105
BD Veritor System FluBecton DickinsonUnited StatesWell + Analyzer13.35–10
Fuji dri-chem immuno AG cartridge FluABMizuho MedyJapanWell + Analyzer21.43–10
Spotchem FLORA FluABArkray-factoryJapanWell + Analyzer13.61.5–10
Sofia Influenza A + B FIADS Pharma BiomedicalUnited StatesWell + Analyzer3015
Influenza rapid diagnosis tests (IRDTs) evaluated in this study.

Viruses

The influenza viruses listed in Table 2 were propagated in MDCK cells, AX4 cells, which express higher amounts of 6-linked sialic acids compared with MDCK cells on their cell surface via exogenous expression of human β-galactoside α2,6-sialyltransferase I (ST6Gal) (Hatakeyama et al., 2005), or chicken embryonated eggs (Table 2). Virus titers (TCID50) were determined by using MDCK cells. Test samples (100 μl) were adjusted to 101–106 TCID50 with Eagle’s minimal essential medium containing 0.3% bovine serum albumin.
TABLE 2

Influenza virus isolates used in this study.

ClassificationVirus strainAbbreviationbPropagated in
Seasonal H1N1pdm09A/Tokyo/UT-HP013/2016H1-1MDCK cells
A/Tokyo/UT-BB131/2017H1-2MDCK cells
A/Tokyo/UT001-1/2018H1-3MDCK cells
Seasonal H3N2A/Tokyo/UT-HP022/2016H3-1MDCK cells
A/Tokyo/UT-HP036/2017H3-2AX4 cells
A/Tokyo/UT002-1/2018H3-3MDCK cells
Seasonal B/VictoriaB/Tokyo/UT-HP009/2016Vic-1MDCK cells
B/Tokyo/UT-DA25-2/2017Vic-2MDCK cells
B/Tokyo/UT-WD028/2018Vic-3MDCK cells
Seasonal B/YamagataB/Tokyo/UT-HP005/2016Yam-1MDCK cells
B/Tokyo/UT-HP053/2017Yam-2MDCK cells
B/Tokyo/UT-HP073/2018Yam-3MDCK cells
H5 virusesA/chicken/Japan/AQ-HE79/2015 (H5N1)aH5-1Embryonated chicken eggs
A/duck/Japan/AQ-HE29-79/2017 (H5N1)aH5-2Embryonated chicken eggs
A/muscovy duck/Aomori/1-3T/2016 (H5N6)aH5-3Embryonated chicken eggs
A/chicken/Niigata/1-1T/2016 (H5N6)aH5-4Embryonated chicken eggs
H7 virusesA/chicken/Kagawa/1T/2018 (H5N6)aH5-5Embryonated chicken eggs
A/Anhui/1/2013 (H7N9)H7-1Embryonated chicken eggs
A/Guangdong/17SF003/2016 (H7N9)aH7-2Embryonated chicken eggs
A/duck/Japan/AQ-HE29-22/2017 (H7N9)aH7-3Embryonated chicken eggs
Influenza virus isolates used in this study.

Biosafety Statements

All experiments with H5N1, H5N6, and H7N9 viruses were performed in biosafety level 3 (BSL3) laboratories at the University of Tokyo, which are approved for such use by the Ministry of Agriculture, Forestry and Fisheries, Japan.

Results and Discussion

We examined the sensitivity of 23 IRDTs commercially available in the 2018–2019 influenza season (Table 1). All of the IRDTs tested employed an immunochromatographic method to detect seasonal influenza A and B viruses. Therefore, the sensitivity of the IRDTs was primarily determined by the binding kinetics of the monoclonal antibody used in the IRDT. RapidTesta FLU⋅NEXT uses a rat monoclonal antibody against the nucleoprotein (NP) of influenza A virus, whereas the others use mouse monoclonal antibodies against the NPs of influenza A and B viruses. Because the epitopes of these monoclonal antibodies on the NP of influenza A virus are conserved among influenza A viruses, 19 of the 23 IRDTs (the exceptions being QuickNavi Flu, QuickNavi-Flu + RSV, Nanotrap Flu A⋅B, and QuickNavi Flu2) claim to be able to detect several animal influenza A viruses, including subtypes H1 through H16, in their appendixes. Although amino acid substitutions in NP are found less frequently than those in HA, NP mutations do occur in seasonal influenza viruses and may affect the sensitivity of IRDTs. The composition of the lysis buffer, the proportion of sample in the analyte, and the method used to visualize the result also affect the sensitivity. The proportion of sample in the analyte is heavily determined by the format of the IRDT; that is, whether it has the test strip format or the well format (Format column, Table 1). The entire test sample can be utilized with the test strip format, whereas the input ratio of the test samples is limited to between 6.7 and 30% for the well format (Input ratio column, Table 1). The method for visualization of the results also differs among the 23 IRDTs: Espline Influenza A&B-N uses alkaline phosphatase and its substrate, Spotchem FLORA FluAB uses a fluorescent latex microsphere, Sofia Influenza A + B FIA uses europium, and the others use gold-, gold plus silver-, gold plus platinum-, or latex-non-fluorescent microspheres for visualization of the immune-complex. The visualized results are assessed by a specific analyzer for QuickNavi Flu2, BD Veritor System Flu, Fuji dri-chem immuno AG cartridge FluAB, Spotchem FLORA FluAB, and Sofia Influenza A + B FIA; the human eye is used for the others (Table 1). All 23 IRDTs requires 1–15 min to complete each test. We examined the sensitivity of these 23 IRDTs for each of three isolates of H1N1pdm09, H3N2, B/Victoria-lineage, and B/Yamagata-lineage isolated between 2016 and 2018 (Table 2). The detection limit of the IRDTs for seasonal H1N1pdm09 and H3N2 viruses ranged from 101 to 106 TCID50 per 100 μl (Table 3). The sensitivity for H3N2 viruses tended to be lower than that for H1N1pdm09 viruses. A similar trend was observed in our previous reports (Sakai-Tagawa et al., 2014, 2017). The detection limit of the IRDTs tested for the B/Victoria- and B/Yamagata-lineages ranged from 102 to 106 TCID50 per 100 μl (Table 3). All tested IRDTs possessed similar sensitivity for B/Victoria- and B/Yamagata-lineages but lower or similar sensitivity for seasonal influenza B viruses compared with that for seasonal influenza A viruses (Table 3). The most sensitive IRDT for seasonal influenza A and B viruses was Sofia Influenza A + B FIA.
TABLE 3

Sensitivity of IRDTs for seasonal influenza A and B virusesa.

IRDTMinimum virus titer (log10 TCID50/100 μl) for a positive result with
H1-1H1-2H1-3H3-1H3-2H3-3Vic-1Vic-2Vic-3Yam-1Yam-2Yam-3
Statmark FLU Stick-N453565544554
RapidTesta colorFLU stick443565544443
QuickVue Rapid SP influ453555544443
Clearview Exact Influenza A&B443565433333
Espline Influenza A&B-N44245443443.53
ImmunoAce Flu442564.54.53.54443
Brightpoc Flu443565544444
Immunofine FLU443565544.5443
QuickNavi Flu443565655555
QuickNavi-Flu + RSV443565655555
Prorast Flu One342454545554
Finevision Influenza443554544443
Nanotrap Flu A⋅B443565544444
Quick Chaser Flu A,B (Type H)442554434443
Alsonic Flu443565544443
Primecheck Flu (Type S)443454544443
RapidTesta FLU⋅NEXT332454433.5443
Spotchem i-Line FluAB-S4435655.555655
QuickNavi Flu2443554.55.555555
BD Veritor System Flu442554433443
Fuji dri-chem immuno AG cartridge FluAB331.53.54.53433.5333
Spotchem FLORA FluAB3324544333.532.5
Sofia Influenza A + B FIA22134342.53332
Sensitivity of IRDTs for seasonal influenza A and B virusesa. We next tested the sensitivity of the 23 IRDTs against H5N1 and H5N6 viruses. The two H5N1 viruses (H5-1 and H5-2) were isolated from raw poultry products that were illegally brought into Japan by international flight passengers (Shibata et al., 2018a) and the three H5N6 viruses (H5-3, H5-4, and H5-5) were isolated from bird feces in Japan (Uchida et al., 2019). These H5 viruses are circulating in avian species and have the potential to transmit to humans (Nunez and Ross, 2019). The detection limit of the 23 IRDTs ranged from 103 to 105 TCID50 per 100 μl for the two H5N1 viruses (H5-1 and H5-2) and from 102 to 106 TCID50 per 100 μl for the three H5N6 viruses (H5-3, H5-4, and H5-5) (Table 4). The sensitivity of the IRDTs for H5-3 and H5-4 was 10–100 lower than that for H5-5. For H7N9 viruses, we used a prototype H7N9 virus (H7-1) that was isolated from the first reported human H7N9 case in 2013 (Gao et al., 2013) and a highly pathogenic H7N9 isolate (H7-2) that emerged and was isolated from a human in 2017 (Zhang et al., 2017; Zhu et al., 2017). Another highly pathogenic H7N9 isolate (H7-3) was isolated in 2017 from Muscovy duck meat, which was brought by passengers from China to Japan (Shibata et al., 2018b). The detection limits of the 23 IRDTs for these H7N9 viruses ranged from 101 to 106 TCID50 per 100 μl (Table 4). The sensitivity of the IRDTs for H7-3 was 100–1000 higher than that for H7-1 and H7-2. Several IRDTs detected the H5 and H7 viruses and the seasonal viruses with similar sensitivity. The most sensitive IRDT for H5Nx and H7N9 viruses was Sofia Influenza A + B FIA.
TABLE 4

Sensitivity of IRDTs for H5 and H7 virusesa.

IRDTMinimum virus titer (log10 TCID50/100 μl) for a positive result with
H5-1H5-2H5-3H5-4H5-5H7-1H7-2H7-3
Statmark FLU Stick-N55664563.5
RapidTesta colorFLU stick55664553
QuickVue Rapid SP influ54664553
Clearview Exact Influenza A&B5465.54453
Espline Influenza A&B-N54554453
ImmunoAce Flu546644.553
Brightpoc Flu54664553
Immunofine FLU54664553
QuickNavi Flu44554453
QuickNavi-Flu + RSV4.545544.553
Prorast Flu One44554453
Finevision Influenza55664553
Nanotrap Flu A⋅B54664553
Quick Chaser Flu A,B (Type H)54664452.5
Alsonic Flu546644.553
Primecheck Flu (Type S)54554452
RapidTesta FLU⋅NEXT44553452
Spotchem i-Line FluAB-S55664563.5
QuickNavi Flu244554453
BD Veritor System Flu54553452
Fuji dri-chem immuno AG cartridge FluAB43552.53.541.5
Spotchem FLORA FluAB4.545.553452
Sofia Influenza A + B FIA43442341
Sensitivity of IRDTs for H5 and H7 virusesa. In this study, all tested IRDTs possessed sufficient sensitivity to detect seasonal H1N1pdm09, H3N2, and type B viruses, as well as H5N1, H5N6, and H7N9 viruses, which are potentially transmittable to humans (Imai et al., 2017; Nunez and Ross, 2019). Most of the IRDTs tested in this study showed similar sensitivity for seasonal influenza A and B viruses as the IRDTs we tested previously (Sakai-Tagawa et al., 2017). Sofia Influenza A + B FIA showed the best sensitivity to all of the influenza A and B viruses tested. Of note, the sensitivity of several of the IRDTs for seasonal influenza viruses differed by 10 times compared with our previous study (Sakai-Tagawa et al., 2017). This difference may be due to modifications of the IRDTs to improve their sensitivity to recent seasonal influenza viruses. Therefore, we need to continue to periodically monitor the sensitivity of IRDTs. The sensitivity of the analyzer-based IRDTs was similar to or better than that of the IRDTs assessed by the human eye. In the case of seasonal viruses, virus titers usually reach 102–106 TCID50 per 100 μl of nasopharyngeal wash during the first 24–72 h of illness (World Health Organization Writing Group et al., 2006). Therefore, all of the IRDTs tested here would, in theory, detect these influenza viruses in patients during this period. However, to detect influenza viruses within 24 h of onset, more sensitive IRDTs are required. Sofia Influenza A + B FIA, Spotchem FLORA FluAB, and Fuji dri-chem immuno AG cartridge FluAB may be suitable for such use because of their higher sensitivity compared with the others. We also need novel rapid detection kits that can detect NA- or PA-inhibitor resistant viruses to help physicians select the most appropriate antiviral therapy. Sofia Influenza A + B FIA detected the H5 and H7 viruses at a high sensitivity, identical to that for seasonal influenza A and B viruses; the detection limit was 101–104 TCID50 per 100 μl, suggesting that this IRDT can diagnose influenza caused by such viruses.

Data Availability Statement

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Author Contributions

YK designed the study. YS-T performed the experiments. YS-T and SY analyzed the data. SY and YK wrote the manuscript. All authors reviewed and approved the manuscript.

Conflict of Interest

YK has received speaker’s honoraria from Toyama Chemical and Astellas Inc.; has received grant support from Chugai Pharmaceuticals, Daiichi Sankyo Pharmaceutical, Toyama Chemical, Tauns Laboratories, Inc., Tsumura & Co., and Denka Seiken Co., Ltd.; and is a co-founder of FluGen. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  21 in total

1.  Viral load and rapid diagnostic test in patients with pandemic H1N1 2009.

Authors:  Masahiro Watanabe; Souichi Nukuzuma; Masahiro Ito; Toshiaki Ihara
Journal:  Pediatr Int       Date:  2011-12       Impact factor: 1.524

2.  Human Infection with a Novel Avian Influenza A(H5N6) Virus.

Authors:  Zi-Feng Yang; Chris K P Mok; Joseph S M Peiris; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2015-07-30       Impact factor: 91.245

3.  Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor.

Authors:  Shuji Hatakeyama; Yuko Sakai-Tagawa; Maki Kiso; Hideo Goto; Chiharu Kawakami; Keiko Mitamura; Norio Sugaya; Yasuo Suzuki; Yoshihiro Kawaoka
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

Review 4.  H5 influenza, a global update.

Authors:  Rhodri Harfoot; Richard J Webby
Journal:  J Microbiol       Date:  2017-02-28       Impact factor: 3.422

Review 5.  Neuraminidase inhibitors: zanamivir and oseltamivir.

Authors:  I R McNicholl; J J McNicholl
Journal:  Ann Pharmacother       Date:  2001-01       Impact factor: 3.154

Review 6.  Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza.

Authors:  Makoto Yamashita
Journal:  Antivir Chem Chemother       Date:  2010

7.  Pathogenesis and Transmission of Novel Highly Pathogenic Avian Influenza H5N2 and H5N8 Viruses in Ferrets and Mice.

Authors:  Joanna A Pulit-Penaloza; Xiangjie Sun; Hannah M Creager; Hui Zeng; Jessica A Belser; Taronna R Maines; Terrence M Tumpey
Journal:  J Virol       Date:  2015-07-29       Impact factor: 5.103

8.  A Highly Pathogenic Avian H7N9 Influenza Virus Isolated from A Human Is Lethal in Some Ferrets Infected via Respiratory Droplets.

Authors:  Masaki Imai; Tokiko Watanabe; Maki Kiso; Noriko Nakajima; Seiya Yamayoshi; Kiyoko Iwatsuki-Horimoto; Masato Hatta; Shinya Yamada; Mutsumi Ito; Yuko Sakai-Tagawa; Masayuki Shirakura; Emi Takashita; Seiichiro Fujisaki; Ryan McBride; Andrew J Thompson; Kenta Takahashi; Tadashi Maemura; Hiromichi Mitake; Shiho Chiba; Gongxun Zhong; Shufang Fan; Kohei Oishi; Atsuhiro Yasuhara; Kosuke Takada; Tomomi Nakao; Satoshi Fukuyama; Makoto Yamashita; Tiago J S Lopes; Gabriele Neumann; Takato Odagiri; Shinji Watanabe; Yuelong Shu; James C Paulson; Hideki Hasegawa; Yoshihiro Kawaoka
Journal:  Cell Host Microbe       Date:  2017-10-19       Impact factor: 21.023

9.  Human infection with a novel avian-origin influenza A (H7N9) virus.

Authors:  Rongbao Gao; Bin Cao; Yunwen Hu; Zijian Feng; Dayan Wang; Wanfu Hu; Jian Chen; Zhijun Jie; Haibo Qiu; Ke Xu; Xuewei Xu; Hongzhou Lu; Wenfei Zhu; Zhancheng Gao; Nijuan Xiang; Yinzhong Shen; Zebao He; Yong Gu; Zhiyong Zhang; Yi Yang; Xiang Zhao; Lei Zhou; Xiaodan Li; Shumei Zou; Ye Zhang; Xiyan Li; Lei Yang; Junfeng Guo; Jie Dong; Qun Li; Libo Dong; Yun Zhu; Tian Bai; Shiwen Wang; Pei Hao; Weizhong Yang; Yanping Zhang; Jun Han; Hongjie Yu; Dexin Li; George F Gao; Guizhen Wu; Yu Wang; Zhenghong Yuan; Yuelong Shu
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245

10.  Non-pharmaceutical interventions for pandemic influenza, international measures.

Authors:  David Bell; Angus Nicoll; Keiji Fukuda; Peter Horby; Arnold Monto; Frederick Hayden; Clare Wylks; Lance Sanders; Jonathan Van Tam
Journal:  Emerg Infect Dis       Date:  2006-01       Impact factor: 6.883

View more
  2 in total

1.  Comparative Sensitivity of Rapid Antigen Tests for the Delta Variant (B.1.617.2) of SARS-CoV-2.

Authors:  Yuko Sakai-Tagawa; Seiya Yamayoshi; Peter J Halfmann; Yoshihiro Kawaoka
Journal:  Viruses       Date:  2021-10-29       Impact factor: 5.048

2.  Seasonal influenza, its complications and related healthcare resource utilization among people 60 years and older: A descriptive retrospective study in Japan.

Authors:  Yuriko Hagiwara; Kazumasa Harada; Joshua Nealon; Yasuyuki Okumura; Takeshi Kimura; Sandra S Chaves
Journal:  PLoS One       Date:  2022-10-03       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.